Michael Gold to Antibodies, Monoclonal
This is a "connection" page, showing publications Michael Gold has written about Antibodies, Monoclonal.
Connection Strength
0.069
-
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. Ann Oncol. 2026 Apr; 37(4):503-520.
Score: 0.052
-
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010 Mar 01; 28(7):1215-23.
Score: 0.017